User:Mr. Ibrahem/Brigatinib
 | |
| Clinical data | |
|---|---|
| Trade names | Alunbrig, others |
| Other names | AP26113 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617016 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Tyrosine kinase inhibitor[1] |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C29H39ClN7O2P |
| Molar mass | 584.10 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Brigatinib, sold under the brand name Alunbrig among others, is a medication used to treat non-small cell lung cancer (NSCLC).[2] Specifically it is used for metastatic cases that are ALK-positive.[2] It is taken by mouth.[2]
Common side effects include diarrhea, tiredness, nausea, rash, muscle pain, headache, high blood pressure, and shortness of breath.[2] Other side effects may include pneumonitis, vision problems, muscle breakdown, pancreatitis, high blood sugar, and sunburns.[2] Use in pregnancy may harm the baby.[2] It is a tyrosine kinase inhibitor that blocks ALK.[1]
Brigatinib was approved for medical use in the United States in 2017 and Europe in 2018.[2][3] In the United Kingdom 4 weeks of medication costs the NHS about £4,900 as of 2021.[4] This amount in the United States is about 17,400 USD.[5]
References[edit]
- ^ a b "Brigatinib Monograph for Professionals". Drugs.com. Retrieved 11 January 2022.
- ^ a b c d e f g h i "DailyMed - ALUNBRIG- brigatinib tablet, film coated ALUNBRIG- brigatinib kit". dailymed.nlm.nih.gov. Archived from the original on 12 May 2021. Retrieved 11 January 2022.
- ^ "Alunbrig". Archived from the original on 11 November 2021. Retrieved 11 January 2022.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1016. ISBN 978-0857114105.
- ^ "Alunbrig Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 11 January 2022.